Novavax Q3 2025 Earnings Report Shows Strategic Shift and Revenue Decline
Novavax reported Q3 2025 earnings with total revenue of $70 million, down from $85 million in the same period in 2024. The decline reflects a strategic shift from direct commercialization to supporting partners like Sanofi, with $57 million in licensing and royalty revenue. The company also announced cost-cutting measures and a campus consolidation expected to generate $60 million in cash proceeds by early 2026.
Topics: business_strategy cost_reduction partnerships revenue